Kamei Koichi, Nozu Kandai, Horinouchi Tomoko, Sakakibara Nana, Nishi Kentaro, Fujita Naoya, Fujinaga Shuichiro, Kaito Hiroshi, Inaba Aya, Hamada Riku, Shima Yuko, Okamoto Takayuki, Hashimoto Junya, Yamamoto Masaki, Gotoh Yoshimitsu, Okuda Yusuke, Kitayama Hirotsugu, Fujimura Junya, Ishimori Shingo, Kamiyoshi Naohiro, Yoshikawa Norishige
Division of Nephrology and Rheumatology, National Center for Child Health and Development, 2-10-1Setagaya-Ku, OkuraTokyo, 157-8535, Japan.
Department of Pediatrics, Kobe University Graduate School of Medicine, Hyogo, Japan.
Pediatr Nephrol. 2025 Jun 5. doi: 10.1007/s00467-025-06842-x.
Genetic analysis, crucial in determining treatment strategies for steroid-resistant nephrotic syndrome (SRNS), can be performed in limited facilities and requires a long time. Predicting the presence or absence of genetic variants by clinical and pathologic features is preferable.
In this multicenter, retrospective study, we compared the clinical or pathologic features between the patients with and without genetic variants in children with SRNS and evaluated the efficacy of immunosuppressive treatment and long-term kidney outcomes.
Fifty-three patients in 17 institutes were included, and 11 patients (21%) showed genetic variants. Two patients with a family history of nephrotic syndrome harbored genetic variants. Serum albumin level at onset was significantly lower in patients without genetic variants (p = 0.001). The receiver operating characteristic curve analysis showed that a cutoff value of serum albumin level of 2.3 g/dL at onset had a sensitivity and specificity of 82% and 90%, respectively, in predicting genetic variants. Patients with asymptomatic proteinuria at onset were more likely to harbor genetic variants (p = 0.05). None of the pathologic features was significantly different between the two groups. Mesangial proliferation and diffuse foot process effacement were observed more in patients without genetic variants, although statistically insignificant. Immunosuppressive treatment was less effective, and the 5-year kidney survival was poorer (31% and 78%, p = 0.03) in patients with genetic variants than in those without genetic variants.
Higher serum albumin levels at onset can predict the presence of genetic variants. Pathologic features might have limited utility in predicting them.
基因分析对于确定激素抵抗型肾病综合征(SRNS)的治疗策略至关重要,但可能在有限的设施中进行且耗时较长。通过临床和病理特征预测基因变异的有无更为可取。
在这项多中心回顾性研究中,我们比较了SRNS患儿中有无基因变异患者的临床或病理特征,并评估了免疫抑制治疗的疗效和长期肾脏预后。
纳入了17家机构的53例患者,11例(21%)显示有基因变异。2例有肾病综合征家族史的患者携带基因变异。无基因变异患者发病时的血清白蛋白水平显著更低(p = 0.001)。受试者工作特征曲线分析显示,发病时血清白蛋白水平的截断值为2.3 g/dL,在预测基因变异时敏感性和特异性分别为82%和90%。发病时有无症状蛋白尿的患者更可能携带基因变异(p = 0.05)。两组间的病理特征均无显著差异。无基因变异患者中系膜增生和弥漫性足突消失更常见,尽管无统计学意义。基因变异患者的免疫抑制治疗效果较差,5年肾脏生存率更低(分别为31%和78%,p = 0.03)。
发病时较高的血清白蛋白水平可预测基因变异的存在。病理特征在预测基因变异方面的作用可能有限。